BRAF and cancer: Retrospective analysis of pts treated at cancer treatment centers with cetuximab plus IR who had previously tested negative for KRAS sequence variants. Primary or secondary endpoints were not defined.PCR with pyrosequencing was used to identify BRAF sequence variants.